Subscribe To Our Newsletter
Subscribe To Our Newsletter
Pfizer reached a $44 million class action settlement resolving allegations that it sold Chantix contaminated with elevated levels of nitrosamines—a potential carcinogen.
If you paid out of pocket for the smoking-cessation drug Chantix between September 2015 and September 2021, you may be eligible to cash in on a new $44 million class action settlement. Pharmaceutical giant Pfizer Inc. reached the agreement to resolve claims that it manufactured and sold Chantix tablets containing undisclosed levels of N-nitroso-varenicline—a probable human carcinogen. You must submit your claim online or postmark it by September 14, 2026, to receive your cash payout.
The lawsuit stems from allegations that Pfizer distributed Chantix (varenicline) that was contaminated with nitrosamines, chemical impurities that can increase the risk of cancer when individuals are exposed to them above acceptable limits over long periods.
The consolidated class action, titled In re Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II) (Case No. 22-MD-3050), was filed in the U.S. District Court for the Southern District of New York. Plaintiffs alleged that Pfizer charged premium prices for a prescription medication that was adulterated and contained dangerous levels of nitrosamine impurities, which were not disclosed to doctors, patients, or health insurance plans.
Pfizer denies all allegations of wrongdoing, maintains that it complied with applicable safety standards, and asserts that it violated no laws. However, to avoid the high cost, uncertainty, and distraction of continued court battles, Pfizer agreed to establish a $44,000,000 settlement fund to compensate affected consumers and third-party payors.
Nitrosamines are organic compounds commonly found in low levels in water and everyday foods, such as cured meats and grilled vegetables. However, regulatory agencies like the U.S. Food and Drug Administration (FDA) set strict daily intake thresholds for nitrosamine impurities in prescription medications because long-term exposure above safety limits is linked to an elevated risk of cancer.
When elevated levels of N-nitroso-varenicline were discovered in Chantix batches, Pfizer voluntarily recalled several lots of the drug, eventually expanding the recall nationwide and pausing global distribution.
The lawsuit alleged that consumers paid for a safe, medically beneficial drug but instead received an adulterated product that did not have the value advertised. By bringing class action litigation, patients and third-party health insurance providers joined forces to demand accountability and recover financial losses associated with purchasing contaminated medications.
The settlement covers all individuals and third-party payors (such as health insurance plans and health funds) who paid any amount of money for retail purchases of branded Chantix in the United States and its territories between September 29, 2015, and September 17, 2021.
You may be eligible to submit a claim if:
You paid an out-of-pocket copay, co-insurance, or full retail price for prescription Chantix during the qualifying timeframe.
You made your purchase within the U.S. or its territories (including Puerto Rico, Guam, and the U.S. Virgin Islands).
You were an individual consumer or a third-party health plan that covered costs for Chantix prescriptions.
If you received Chantix completely free of charge through a patient assistance program, coupon, or insurance arrangement where you had zero out-of-pocket cost, you are not eligible for financial compensation.
The $44 million settlement fund will cover consumer cash payments, administrative expenses, notice costs, court-approved attorney fees, and service awards for the class representatives.
Individual consumer payouts will be calculated on a pro rata basis depending on the total dollar amount you spent out of pocket for Chantix during the eligibility period. Key guidelines governing individual payouts include:
Consumer Allocation: Total consumer claims will be capped at 20% of the Available Settlement Fund, with remaining funds allocated to third-party payors based on documented prescription costs.
Maximum Payout Cap: No individual consumer’s payout will exceed the actual total amount they paid out of pocket for Chantix during the settlement period.
Pro Rata Distribution: If total valid claims exceed the available consumer fund portion, individual payments will adjust proportionally based on submitted purchase documentation.
Providing receipts, pharmacy records, or insurance explanation of benefits (EOB) statements with your claim form will help verify your total spending and ensure you receive the maximum payout allowed.
Filing a claim is simple, free, and can be completed digitally in a few minutes. To secure your share of the settlement, follow these step-by-step instructions:
Visit the Official Settlement Site: Go directly to the court-monitored portal at ChantixSettlement.com.
Complete the Claim Form: Enter your contact details and select whether you are claiming as an individual consumer or a third-party payor.
Provide Purchase Details: List the dates and amounts you paid out of pocket for Chantix between September 29, 2015, and September 17, 2021.
Attach Supporting Documents: Upload pharmacy receipts, EOB forms, or prescription history logs showing your payments if you have them available.
Select Your Payment Option: Choose how you would like to receive your payment (electronic transfer or mailed check) and submit the form.
If you prefer to submit a paper claim, you can download a printable PDF form from the settlement website, fill it out, and mail it to the settlement administrator: Chantix Settlement Administrator, P.O. Box 173001, Milwaukee, WI 53217.
To protect your legal rights and ensure you receive a payment, keep these crucial dates in mind:
Claim Form Deadline: All claims must be submitted online or postmarked no later than September 14, 2026.
Opt-Out Deadline: If you wish to exclude yourself from the settlement to preserve your right to sue Pfizer independently, your written request must be postmarked by September 14, 2026.
Objection Deadline: If you want to object to any terms of the settlement while remaining in the class, your written objection must be postmarked by September 14, 2026.
Final Approval Hearing: The court will hold a fairness hearing on October 13, 2026, at 3:00 p.m. to decide whether to give final approval to the $44 million deal.
Payments will be distributed only after the court grants final approval and any potential appeals are fully resolved. Missing the September 14, 2026 claim deadline means you will give up your right to receive a cash payout.
New cases and investigations, settlement deadlines, and news straight to your inbox.
